Search Results - "Paradiso, Peter R"

Refine Results
  1. 1

    Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy by Fletcher, Mark A, Schmoele-Thoma, Beate, Vojicic, Jelena, Daigle, Derek, Paradiso, Peter R, Del Carmen Morales, Graciela

    Published in Expert review of vaccines (31-12-2024)
    “…There was no 13-valent pneumococcal conjugate vaccine (PCV13) adult antibody concentration threshold regulatory criterion for licensure - unlike the pediatric…”
    Get full text
    Journal Article
  2. 2

    Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children by Paradiso, Peter R.

    Published in Clinical infectious diseases (15-05-2011)
    “…A 13-valent pneumococcal conjugate vaccine (PCV13), developed with the same chemistry used for the 7-valent PCV vaccine (PCV7) and with the goal of expanding…”
    Get full text
    Journal Article
  3. 3

    Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants by Rennels, Margaret B, Edwards, Kathryn M, Keyserling, Harry L, Reisinger, Keith S, Hogerman, Deborah A, Madore, Dace V, Chang, Ih, Paradiso, Peter R, Malinoski, Frank J, Kimura, Alan

    Published in Pediatrics (Evanston) (01-04-1998)
    “…To determine the safety and immunogenicity of heptavalent pneumococcal saccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) individually conjugated to…”
    Get full text
    Journal Article
  4. 4

    Pneumococcal Conjugate Vaccine for Adults: A New Paradigm by Paradiso, Peter R.

    Published in Clinical infectious diseases (15-07-2012)
    “…A 13-valent pneumococcal conjugate vaccine has been studied in adults aged ≥50 years to compare the immune response to that induced by the 23-valent…”
    Get full text
    Journal Article
  5. 5

    Establishing Government-Operated Vaccine Programs: An Industry Perspective by Paradiso, Peter R

    Published in Clinical infectious diseases (01-03-2006)
    “…During 2000–2002, shortages of numerous routinely administered pediatric vaccines occurred. The reasons for these shortages were varied, but they included…”
    Get full text
    Journal Article
  6. 6

    Pneumococcal conjugate vaccine in adults: Let's see what happens by Paradiso, Peter R.

    Published in Human vaccines & immunotherapeutics (02-07-2016)
    “…The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for…”
    Get full text
    Journal Article
  7. 7

    Safety and Immunogenicity of a Purified F Protein Respiratory Syncytial Virus (PFP-2) Vaccine in Seropositive Children with Bronchopulmonary Dysplasia by Groothuis, Jessie R., King, Susan J., Hogerman, Debbie A., Paradiso, Peter R., Simoes, Eric A. F.

    Published in The Journal of infectious diseases (01-02-1998)
    “…Respiratory syncytial virus (RSV) causes serious respiratory illness in preterm children with bronchopulmonary dysplasia. In a prospective randomized…”
    Get full text
    Journal Article
  8. 8

    Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I by Hausdorff, William P., Bryant, John, Paradiso, Peter R., Siber, George R.

    Published in Clinical infectious diseases (01-01-2000)
    “…We analyzed >70 recent data sets to compare the serogroups causing invasive pneumococcal disease (IPD) with those represented in conjugate vaccine…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children by Hausdorff, William P, Siber, George, Paradiso, Peter R

    Published in The Lancet (British edition) (24-03-2001)
    “…The development of glycoconjugate vaccines for Streptococcus pneumoniae that are effective in very young children has renewed interest in identification of…”
    Get full text
    Journal Article
  11. 11

    The Contribution of Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for Conjugate Vaccine Formulation and Use, Part II by Hausdorff, William P., Bryant, John, Kloek, Carolyn, Paradiso, Peter R., Siber, George R.

    Published in Clinical infectious diseases (01-01-2000)
    “…To assess whether certain serogroups of Streptococcus pneumoniae are preferentially associated with specific disease manifestations, we analyzed all recent…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Recent progress in the development of vaccines for infants and children by McIntosh, E.David G, Paradiso, Peter R

    Published in Vaccine (30-01-2003)
    “…Infectious agents do not respect national or international boundaries. Attempts to prevent their spread, and the diseases which they cause, involve…”
    Get full text
    Journal Article Conference Proceeding
  15. 15
  16. 16

    The future of polio immunization in the United States: are we ready for change? by PARADISO, PETER R

    Published in The Pediatric infectious disease journal (01-08-1996)
    “…During the past 6 months there has been considerable debate within the infectious disease community about the current and future recommendations for polio…”
    Get full text
    Journal Article Conference Proceeding
  17. 17

    Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants by PARADISO, P. R, HOGERMAN, D. A, MADORE, D. V, KEYSERLING, H, KING, J, REISINGER, K. S, BLATTER, M. M, ROTHSTEIN, E, BERNSTEIN, H. H, HACKELL, J

    Published in Pediatrics (Evanston) (01-12-1993)
    “…To study the safety and immunogenicity of a combined diphtheria-tetanus-pertussis (DTP)-Haemophilus influenzae type b (HbOC) vaccine (TETRAMUNE) in infants as…”
    Get full text
    Journal Article
  18. 18

    Combined Childhood Immunizations by Paradiso, Peter R

    “…To the Editor.—The recent article by Clemens et al1 states the need for care when assessing potential interference in combination of or even simultaneous…”
    Get full text
    Journal Article
  19. 19

    The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants by Kale, K L, King, Jr, J C, Farley, J J, Vink, P E, Cimino, C O, Paradiso, P R

    Published in The Pediatric infectious disease journal (01-05-1995)
    “…Enzyme-linked immunosorbent assay polyribosyl ribitol phosphate (PRP) antibody responses to Haemophilus influenzae type b conjugate vaccine (HbOC) given at 2,…”
    Get more information
    Journal Article
  20. 20